Test your knowledge of treatment persistence, adherence, and switching patterns of adalimumab biosimilar ABP 501 between adalimumab-naïve patients and adalimumab-experienced patients.
A retrospective analysis examined pharmacy claims data from Germany and France, focusing on adult patients with inflammatory bowel disease (IBD) who initiated treatment with ABP 501, an adalimumab biosimilar, between October 2018 and March 2020. The study assessed treatment persistence, adherence, and switching patterns for two groups: adalimumab-naïve patients and adalimumab-experienced patients.
Test your knowledge of ABP 501 with this quiz:
What was the overall switch rate within the first 12 months of ABP 501 initiation in the French patient population?